KCI Senior Leadership is composed of three scientific Associate Center Directors (ACDs) for Basic Sciences (Dr. Wei-Zen Wei), Clinical Sciences (Dr. Anthony Shields) and Population Sciences (Dr. Terrance Albrecht). A new senior leadership position, Scientific Director of Cores, has been added (Dr. Fred Miller) with responsibility for oversight and scientific leadership for the Cancer Center Cores. They are all supported by an ACD for Research Administration (Ms. Constance Claybaker) and overseen by the Deputy Center Director, Dr. Ann Schwartz. As President, CEO, and Center Director of the Karmanos Cancer Institute, Dr. Gerold Bepler bears ultimate responsibity for the administration and fiscal management of all KCI resources, including budgeting, personnel and faculty appointments, and space and equipment allocations. The primary responsibility of this team lies in ensuring that all of the Center's resources are optimally deployed to enhance the development of outstanding science as well as intra- and inter-programmatic interactions. These broad areas, each composed of more specific interests for investigation, define the role of the Senior Leaders to ensure the successful completion of broader scientific goals of the Institution through an active portfolio of individual Programs. The ACDs, by participating in such strategic committees as the ACD Committee, President's Committee, and Scientific Leadership Council, support ongoing discussions and debates about the allocation of resources. In addition, the scientific ACDs, oversee a discretionary fund of $750,000 annually to support pilot studies, the new post-doctoral program and recruitment opportunities during the year. Support is requested for Senior Leadership: Dr. Bepler (50% effort, 25% funding), Dr. A. Schwartz (25% effort, 10% funding), Dr. Wei (10% effort and funding), Dr. Shields (10% effort and funding), Dr. Albrecht (10% effort and funding), Ms. Claybaker (10% effort and funding) and Dr. F. Miller (25% effort and funding). Two of the scientific ACDs also serve as Program Leaders and funds for those efforts are requested elsewhere as is the funding for Ms. Claybaker as ACD of Research Administration.
Members of Senior Leadership oversee the mission and strategic plans for the KCI scientific community. The team ensures all KCI resources are optimally deployed to enhance the development of outstanding science.
|Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70|
|Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660|
|Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693|
|Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481|
|Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562|
|Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294|
|Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :|
|Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :|
|Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008|
|Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017|
Showing the most recent 10 out of 826 publications